Cost-effectiveness of colon capsule endoscopy in colorectal cancer screening: a modeling study

Abstract

Background

The most used primary colorectal cancer (CRC) screening tests are the fecal immunochemical test (FIT) and colonoscopy. However, colonoscopy is an invasive procedure with possible (fatal) complications and FIT has shortcomings in test sensitivity. Colon capsule endoscopy (CCE) could be an alternative, but long-term effects are unknown. We assessed the cost-effectiveness of CCE in CRC screening.

Methods

We simulated a Dutch cohort born between 1938 and 1957 for eight strategies: biennial FIT screening with cutoffs of 15 (FIT15) and 47 (FIT47) micrograms of hemoglobin per gram feces (µg Hb/g); biennial and triennial CCE screening; CCE after a FIT-negative result of 15–47 µg Hb/g (CCE triage); CCE after positive FIT using 15 and 47 µg Hb/g cutoffs; and 10-yearly colonoscopy screening. Three adherence scenarios were considered. We estimated lifetime CRC incidence, mortality, life years gained, and number of tests required. A cost-effectiveness analysis was performed to determine cost-effectiveness of each strategy.

Results

Triennial CCE and CCE triage screening had similar long-term outcomes to biennial FIT47. At 100% adherence, biennial CCE screening reduced CRC incidence from 79 to 49 cases (38.0% reduction) and mortality from 36 to 17 deaths (52.8% reduction) per 1000 individuals versus no screening. Life years gained increased to 155 per 1000 individuals versus 115 with biennial FIT47 (34.8% increase). However, these increases came at high financial cost, and CCE cost-effectiveness was dominated by biennial FIT and 10-yearly colonoscopy.

Conclusion

CCE was not cost effective for CRC screening compared with biennial FIT and 10-yearly colonoscopy.

Publikationsverlauf

Eingereicht: 04. Dezember 2024

Angenommen nach Revision: 22. Mai 2025

Artikel online veröffentlicht:
01. August 2025

• References

• 1 Adler DG, Chand B, Conway JD. et al. Capsule endoscopy of the colon. Gastrointest Endosc 2008; 68: 621-623
• 2 Vuik FER, Nieuwenburg SAV, Moen S. et al. Colon capsule endoscopy in colorectal cancer screening: a systematic review. Endoscopy 2021; 53: 815-824
• 3 Cash BD, Fleisher MR, Fern S. et al. Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study). Gut 2021; 70: 2115-2122
• 4 Vuik FER, Nieuwenburg SAV, Moen S. et al. Population-based prevalence of gastrointestinal abnormalities at colon capsule endoscopy. Clin Gastroenterol Hepatol 2022; 20: 692-700 e7
• 5 Meester RGS, van de Schootbrugge-Vandermeer HJ, Breekveldt ECH. et al. Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. Gut 2023; 72: 101-108
• 6 van Hees F, Zauber AG, van Veldhuizen H. et al. The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. Gut 2015; 64: 1985-1997
• 7 Loeve F, Boer R, van Oortmarssen GJ. et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999; 32: 13-33
• 8 Arminski TC, McLean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum 1964; 7: 249-261
• 9 Blatt LJ. Polyps of the colon and rectum. Dis Colon Rectum 1961; 4: 277-282
• 10 Bombi JA. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer 1988; 61: 1472-1476
• 11 Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg 1963; 157: 223
• 12 Clark JC, Collan Y, Eide TJ. et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 1985; 36: 179-186
• 13 Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut 1992; 33: 1508-1514
• 14 Johannsen LGK, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. Scand J Gastroenterol 1989; 24: 799-806
• 15 Rickert RR, Auerbach O, Garfinkel L. et al. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 1979; 43: 1847-1857
• 16 Stoop EM, de Haan MC, de Wijkerslooth TR. et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012; 13: 55-64
• 17 Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982; 49: 819-825
• 18 Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982; 23: 835-842
• 19 Peterse EFP, Meester RGS, de Jonge L. et al. Comparing the cost-effectiveness of innovative colorectal cancer screening tests. J Natl Cancer Inst 2021; 113: 154-161
• 20 Rex DK, Adler SN, Aisenberg J. et al. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. Gastroenterology 2015; 148: 948-957 e942
• 21 Vuik FER, Moen S, Nieuwenburg SAV. et al. Applicability of colon capsule endoscopy as pan-endoscopy: from bowel preparation, transit, and rating times to completion rate and patient acceptance. Endosc Int Open 2021; 9: E1852-E1859
• 22 van Rijn JC, Reitsma JB, Stoker J. et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101: 343-350
• 23 van Iersel C, Toes-Zoutendijk E, de Jonge L. et al. National evaluation of the population-based colorectal cancer screening programme 2018–2021. National Evaluation Team for Colorectal Cancer Screening (LECO). The second evaluation report January 2023. Accessed: July 2025. https://www.rivm.nl/sites/default/files/2023–05/Evaluation%20of%20the%20Colorectal%20Cancer%20Screening%20Programme%202018–2021.pdf
• 24 Omidvari A-H, Roumans CAM, Naber SK. et al. The impact of the policy-practice gap on costs and benefits of Barrett’s esophagus management. Am J Gastroenterol 2020; 115: 1026
• 25 De Kok I, Polder JJ, Habbema JDF. et al. The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer 2009; 100: 1240-1244
• 26 Lansdorp-Vogelaar I, Van Ballegooijen M, Zauber AG. et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009; 101: 1412-1422
• 27 Moen S, Vuik FER, Voortman T. et al. Predictors of gastrointestinal transit times in colon capsule endoscopy. Clin Transl Gastroenterol 2022; 13: e00498
• 28 Hassan C, Zullo A, Winn S. et al. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer. Endoscopy 2008; 40: 414-421